Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility
Draxis Pharma, the pharmaceutical contract manufacturing division of Draxis Health Inc. (Mississauga, ON, Canada), has extended its scheduled summer maintenance shutdown of its sterile and lyophilized product manufacturing areas. The shutdown was extended to allow the company to replace a major electrical panel and a pump assembly, and to perform "further cleaning and decontamination of the sterile production area," according to a company statement. The shutdown, originally scheduled to last two to three weeks, is now expected to last five to seven weeks. Company officials declined to provide additional details until they issue a follow-up announcement about the resumption of production.
–Laura Bush
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.